Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07182149 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Normunity AccelCo.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 9
- Study locations
NCT07182149 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Normunity AccelCo. The registered enrollment target is 150 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT07182149, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Normunity AccelCo.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG NRM-823
Study Locations (9)
Texas
- Normunity Investigational Site - Dallas
- Normunity Investigational Site - San Antonio
Colorado
- Normunity Investigational Site - Denver
Connecticut
- Normunity Investigational Site - New Haven
Minnesota
- Normunity Investigational Site - Minneapolis
Ohio
- Normunity Investigational Site - Maumee
Pennsylvania
- Normunity Investigational Site - Philadelphia
Tennessee
- Normunity Investigational Site - Nashville
Virginia
- Normunity Investigational Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2028-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07182149
The ClinicalTrials.gov registry entry for NCT07182149 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% lower). The listed sponsor is Normunity AccelCo, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which NRM-823 is the first listed.
NCT07182149 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Texas, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07182149 about?
NCT07182149 is a clinical study titled "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors". This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
What is the current status of trial NCT07182149?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-10-30. Estimated completion is 2028-10-31.
What conditions does trial NCT07182149 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancer, NSCLC, Gastric Adenocarcinoma.
What interventions are being tested in trial NCT07182149?
The interventions under investigation include: NRM-823 (DRUG).
Who is sponsoring clinical trial NCT07182149?
This trial is sponsored by Normunity AccelCo, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07182149 being conducted?
This trial has 9 study locations across Colorado, Connecticut, Minnesota, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.